Mesoblast Shares Rise As Remestemcel-L Cuts Mortality In Patients Below 65 Years With COVID-19 Related Respiratory Distress

  • Mesoblast Limited MESO has announced 60-day results from the randomized controlled trial of remestemcel-L in COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS), which had been halted after the third interim analysis, as previously announced.
  • The trial enrolled 222 mechanically ventilated COVID-19 patients.
  • Remestemcel-L reduced mortality by 46% through day 60 in the pre-specified population of 123 treated patients under age 65, 26% vs. 42%, Hazard Ratio (HR) 0.54.
  • The treatment has similar effects on mortality in these patients with either moderate ARDS (HR 0.56) or severe ARDS (HR 0.56).
  • The standard of care changed during the course of the trial to incorporate dexamethasone.
  • Remestemcel-L reduced mortality through day 60 by 75% compared to controls in patients under 65 who received dexamethasone as part of their standard of care, 14% vs. 45%, HR 0.25.
  • Remestemcel-L increased days alive off the ventilator within 60 days and reduced time to discharge from initial hospitalization compared to controls in patients under 65 who received dexamethasone.
  • Mesoblast entered into a license and collaboration agreement with Novartis AG NVS for the development, manufacture, and commercialization of remestemcel-L, with an initial focus on treating ARDS, including that associated with COVID-19.
  • The company will hold a webcast at 9 A.M ET today.
  • Price Action: MESO shares are up 5.1% at $7.59 in the premarket on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefsCovid-19
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!